| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/125.1.12 |
| P953 | full work available at URL | http://academic.oup.com/jid/article-pdf/125/1/12/2449367/125-1-12.pdf |
| P698 | PubMed publication ID | 4550416 |
| P2093 | author name string | H. L. DuPont | |
| E. J. Gangarosa | |||
| J. P. Libonati | |||
| S. B. Formal | |||
| R. B. Hornick | |||
| M. J. Snyder | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| attenuated vaccine | Q1810913 | ||
| P304 | page(s) | 12-16 | |
| P577 | publication date | 1972-01-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection | |
| Immunity in Shigellosis. II. Protection Induced by Oral Live Vaccine or Primary Infection | |||
| P478 | volume | 125 |
| Q47205506 | A clinically parameterized mathematical model of Shigella immunity to inform vaccine design. |
| Q24647116 | Alternative hand contamination technique to compare the activities of antimicrobial and nonantimicrobial soaps under different test conditions |
| Q34669980 | Applying mathematical tools to accelerate vaccine development: modeling Shigella immune dynamics |
| Q39519924 | Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection |
| Q37427662 | Bacterial colitis |
| Q33608118 | Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection |
| Q93075052 | Clinical endpoints for efficacy studies |
| Q54246807 | Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score. |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q34478002 | Comparative Immunogenicity of Heat-Killed and Living Oral Salmonella Vaccines |
| Q50121553 | Comparison of six dose-response models for use with food-borne pathogens |
| Q39232647 | Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants |
| Q91801435 | Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q91801450 | Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays |
| Q34545910 | Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine |
| Q39573053 | Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model |
| Q37037721 | Cytotoxicity of human peripheral blood and colostral leukocytes against Shigella species |
| Q40880560 | Detection of a leukocytic endogenous mediator-like mediator of serum amino acid and zinc depression during various infectious illnesses |
| Q35469131 | Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide. |
| Q36339944 | Dose-response relationships for environmentally mediated infectious disease transmission models |
| Q37458618 | Effect of wild-type Shigella species and attenuated Shigella vaccine candidates on small intestinal barrier function, antigen trafficking, and cytokine release |
| Q37166078 | Epidemic spread of Shigella sonnei shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz) |
| Q37066116 | Establishment of a Shigella sonnei human challenge model in Thailand |
| Q39247229 | Evaluation of an Intervention Program in the Control of an Urban Outbreak of Shigellosis |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q33262196 | Immunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T. |
| Q35480510 | Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier |
| Q36890938 | Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics |
| Q40598013 | Intestinal immunoglobulin A responses in rabbits to a Salmonella typhi strain harboring a Shigella sonnei plasmid |
| Q35598035 | Live attenuated Shigella dysenteriae type 1 vaccine strains overexpressing shiga toxin B subunit |
| Q35772614 | Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. |
| Q69255339 | Long-Term Shigella-Carrier State |
| Q57925750 | Malnutrition is a determining factor in diarrheal duration, but not incidence, among young children in a longitudinal study in rural Bangladesh |
| Q39863172 | Microbiological Hazards of Household Toilets: Droplet Production and the Fate of Residual Organisms |
| Q34129475 | Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector |
| Q36365336 | Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis |
| Q33628356 | New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development |
| Q46799503 | Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers. |
| Q37125747 | Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei |
| Q35924773 | Production of a Shigella sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB |
| Q36966451 | Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. |
| Q40211202 | Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis |
| Q40614472 | Role of antigen form in development of mucosal immunoglobin A response to Shigella flexneri Antigens |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q84554549 | Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q36945836 | Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. |
| Q35528270 | Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q35225017 | Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm. |
| Q36920244 | Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a. |
| Q34003433 | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q92968788 | Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses |
| Q56383780 | Shigellosis |
| Q54291146 | Shigellosis in custodial institutions. 3. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated shigella vaccines. |
| Q41452318 | Shigellosis: from molecular pathogenesis of infection to protective immunity and vaccine development |
| Q36989057 | Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains |
| Q36985066 | Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei |
| Q34518265 | Status of vaccine research and development for Shigella |
| Q34000330 | Strategy for cross-protection among Shigella flexneri serotypes |
| Q33607442 | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid |
| Q52657631 | T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. |
| Q38035961 | The Shigella human challenge model |
| Q33955468 | The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies |
| Q74778792 | Topics in microbial risk assessment: dynamic flow tree process |
| Q33876803 | Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 |
| Q39950952 | Vaccines and cell-mediated immunity |
Search more.